GDRX vs PHVS

GoodRx Holdings, Inc.

(GDRX) offers the better valuation at 33. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Pharvaris N. V. (PHVS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pharvaris N.

V. (PHVS) delivered a total return of +31. 2%, compared to -91. 8% for GoodRx Holdings, Inc. (GDRX). Over 10 years, the gap is even starker: PHVS returned +2. 3% versus GDRX's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pharvaris N.

V. (PHVS) is the lower-risk stock at 1. 02β versus GoodRx Holdings, Inc. 's 1. 58β — meaning GDRX is approximately 55% more volatile than PHVS relative to the S&P 500. On balance sheet safety, Pharvaris N. V. (PHVS) carries a lower debt/equity ratio of 0% versus 10% for GoodRx Holdings, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc.

grew EPS 104. 1% year-over-year, compared to 5. 7% for Pharvaris N. V.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GoodRx Holdings, Inc.

(GDRX) is the more profitable company, earning 3. 8% net margin versus 0. 0% for Pharvaris N. V. — meaning it keeps 3. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus 0. 0% for PHVS. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PHVS: 47.

1% to $43. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Pharvaris N.

V. (PHVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02)). GoodRx Holdings, Inc. (GDRX) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PHVS: +2. 3%, GDRX: -94. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.